Navigation Links
Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
Date:1/23/2009

ROCKVILLE, Md., Jan. 23 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Penny Heaton, V.P., and Chief Medical Officer, will be presenting at the Phacilitate Vaccine Forum Washington 2009 conference on January 26, 2009 at the Grand Hyatt in Washington D.C. Dr. Heaton is participating in the Focus Session 'What benefits are single-use technologies and other novel vaccine manufacturing solutions providing in practice' and will be speaking to the Case Study: Virus-Like Particle (VLP) based vaccines for pandemic and seasonal influenza. Slides from the presentation will be posted on the Novavax website at www.novavax.com.

There are several reasons for utilizing virus-like particle technology as a vaccine platform. Recombinant technology permits tailoring of vaccines to contain only those proteins that are immunologically important for protection and structurally important for optimizing expression and yields. In addition, preclinical and clinical data have shown that VLPs activate multiple arms of the immune system, inducing robust humoral and cell-mediated immunity, which permits vaccine development for a wide range of disease targets. Further, VLPs may be more cost effective to produce because vaccines against different disease targets may be manufactured utilizing the same process and facility. Dr. Heaton's presentation will discuss these advantages, with a specific focus on the potential immunologic and manufacturing benefits of Novavax's pandemic and seasonal influenza VLP vaccines.

ABOUT NOVAVAX

Novavax, Inc. (Nasdaq: NVAX) is a clinical stage biotechnology company, creating novel vaccines to addre
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
2. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
3. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
4. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
5. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
6. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
7. Novavax CEO to Present at BIO Investor Forum 2008
8. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
9. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
10. Novavax Announces Closing of $18 Million Registered Direct Offering
11. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... , May 19, 2015 Research and Markets ... the "Global Cell Therapy Market Outlook 2020 " ... cell therapy in tissue and regenerative medicine is expected ... other options which could help in the growth of ... segment but they are unable to form new tissue ...
(Date:5/20/2015)... The global genotyping market is expected to grow ... of 2015 to 2020 to reach $17.0billion in 2020. ... and development process and to provide personalized therapy, factors ... investments by key manufacturers to offer advanced and innovative ... Browse 113 market data tables & 37 figures spread ...
(Date:5/20/2015)... Agricultural firm H.J. Baker & Bro., Inc. today ... Since the purchase of Tiger Industries and Tiger-Sunbelt ... H.J. Baker has leveraged the innovation of the Tiger-Sul ... of product offerings and solutions expertise. The deal brought ... of Tiger-Sul, transforming the company into a leading enterprise ...
(Date:5/20/2015)... 20, 2015  Haemonetics Corporation (NYSE: HAE ) ... CEO, will present at The Jefferies 2015 Global Healthcare ... June 1 st , 2015 at 8:30am Eastern time.  ... presentation live via webcast at: http://wsw.com/webcast/jeff88/hae ... HAE ) is a global healthcare company dedicated to ...
Breaking Biology Technology:Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3
... The continued expansion of oil palm plantations will worsen ... loss, unless rainforests are better protected, warn scientists in ... , Lead author, Emily Fitzherbert from the Zoological Society ... has been much debate over the role of palm ...
... Cequent Pharmaceuticals, a,pioneer in the development of novel ... human disease, announced that it has met,its second ... Option Fund,and will move on to the next ... using Cequent,s proprietary TransKingdom RNA,interference [tkRNAi(TM)] technology in ...
... WARSAW, Ind., Sept. 15 Symmetry Medical Inc.,(NYSE: ... the global,orthopedic device industry and other medical markets, announced ... is scheduled to,present at the UBS Global Life Sciences ... City on Thursday, September 25, 2008 at 11:30 a.m. ...
Cached Biology Technology:Oil palm plantations are no substitute for tropical rainforests, a new study shows 2Oil palm plantations are no substitute for tropical rainforests, a new study shows 3Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo 2Symmetry Medical to Present at UBS Global Life Sciences Conference 2
(Date:5/19/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
(Date:5/14/2015)... NEW YORK , May 14, 2015 ... specializing in identity verification and online remote ... Instructure, a software-as-a-service (SaaS) company and creator ... Shared customers of the two companies will ... Proctortrack in Canvas. As a ...
(Date:5/8/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leading ... the executive management team will present at the following investor ... Telecom Conference Date: May 18, 2015 Time: 10:40am ... Cowen and Company Technology, Media & ... The New York Palace Hotel, New York, NY ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
... Chinese government regulators had clearer skies and easier breathing ... temporarily shuttered some factories and banished many cars in ... that,s what they got. They were not ... satellites to measure the impact of air pollution controls. ...
... of Rochester Medical Center scientists discovered a gene mutation that ... according to a study published online December 16, 2008, in ... The investigation is the first to link the key ... defective in 50 percent of all cancers. Until now, ...
... COLUMBIA, Mo. According to the National Institute ... more common than schizophrenia or bipolar disorder and ... population. In a new study, a University of ... found that genetic material on chromosome nine was ...
Cached Biology News:New satellite data reveal impact of Olympic pollution controls 2New satellite data reveal impact of Olympic pollution controls 3Study of placenta unexpectedly leads to cancer gene 2MU researcher identifies possible genetic causes of borderline personality disorder 2
Acid phosphatase (Potato). Monospecific by IEP. Some cross reactivity between Acid phosphatases of other species may occur....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
... [YPF19] to Yersinia pestis This ... pestis . Immunogen: ... pestis vaccine strain EV76. ... Y.pestis F1 capsular antigen. There is ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Biology Products: